Table 2 Favourable and poor outcome in surviving patients categorised by diagnosis.
| Disability (Rankin score) n (%)* | Muscle strength (MRC sum score) n (%) | Quality of life (phSIP) n (%) | Treatment at FU n (%) | |||||
|---|---|---|---|---|---|---|---|---|
| 0–1 | 3–5 | 130 | <128 | <1.6% | >10.8%† | No | Yes‡ | |
| PM (n = 6) | ||||||||
| Isolated (n = 6) | 0 (0) | 2 (33) | 2 (33) | 3 (50) | 1 (17) | 5 (83) | 2(33) | 1(17) |
| + CTD (n = 0) | — | — | — | — | — | — | — | — |
| + mal (n = 0) | — | — | — | — | — | — | — | — |
| DM (n = 41) | ||||||||
| Isolated (n = 37) | 14 (38) | 6 (16) | 22 (60) | 9 (24) | 8 (22) | 17 (46) | 14(38) | 15(41) |
| + CTD (n = 3) | 2 (67) | 0 (0) | 3 (100) | 0 (0) | 0 (0) | 1 (33) | 2(67) | 0(0) |
| + mal (n = 1) | 1(100) | 0 (0) | 1 (100) | 0 (0) | 0 (0) | 0 (0) | 1(100) | 0(0) |
| Unsp myositis (n = 40) | ||||||||
| Isolated (n = 24) | 7 (29) | 8 (33) | 17 (71) | 7 (29) | 5 (22) | 11 (47) | 9(38) | 11(46) |
| + CTD (n = 16) | 3 (19) | 3 (19) | 13 (81) | 1 (6) | 2 (13) | 10 (63) | 3(19) | 8(50) |
| + mal (n = 0) | — | — | — | — | — | — | — | — |
| Poss myositis (n = 23) | ||||||||
| Isolated (n = 21) | 9 (43) | 6 (29) | 12 (57) | 6 (29) | 1 (5) | 8 (42) | 9(43) | 9(43) |
| + CTD (n = 2) | 1 (50) | 1 (50) | 1 (50) | 1 (50) | 0 (0) | 1 (50) | 1(50) | 1(50) |
| + mal (n = 0) | — | — | — | — | — | — | — | — |
| Total (%) | 37 (34) | 26 (24) | 71 (65) | 27 (25) | 17 (16) | 53 (51) | 41(37) | 45(41) |
CTD, connective tissue disorder; DM, dermatomyositis; FU, follow‐up; mal, malignancy; MRC, Medical Research Council; phSIP, physical dimension of the Sickness Impact Profile (mean phSIP score in healthy persons is 1.6%,31 median phSIP score in our study population was 10.8%, three missing values); PM, polymyositis (defined by endomysial cell infiltrates); Poss myositis, possible myositis (clinical PM with necrotising myopathy); Unsp myositis, unspecified myositis (clinical PM, with perimysial and perivascular cell infiltrates); +, with.
*Values are given for favourable and poor outcome; number of patients with neither a poor nor a favourable outcome are not shown.
†Median physical SIP score in total population.
‡Prednisone >10 mg/day or immunosuppressive drug.